| Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. | |
| | |
MedLine Citation:
|
PMID: 21335294 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background: Achievement of glycemic control in elderly patients with type 2 diabetes mellitus (DM) is complicated by many factors. Objective: The aim of this article was to systematically review evidence on the effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors (ie, lowering of glycosylated hemoglobin [HbA(1c)]), the risk of hypoglycemia associated with these agents, and the effects of these agents on body weight in elderly patients with type 2 DM. Methods: The PubMed and Biosis databases were searched for reports of clinical trials and meeting presentations (eg, abstracts, posters) published in English between January 1, 2000, and October 25, 2009, that included elderly patients with type 2 DM who were treated with sitagliptin, saxagliptin, vildagliptin, alogliptin, BI-1356, DSP-7238, or PF-734200. Pharmacokinetic and pharmacodynamic studies were excluded from the review, as were studies that did not specifically provide quantitative clinical data on glycemic parameters or specifically list patients aged ≥65 years. Results: Eighty-five articles and 5 presentations were identified in the search; of those, 18 articles and 3 presentations were included in the review. These publications described studies of DPP-4 inhibitors administered as monotherapy or in combination with metformin, a thiazolidinedione, glimepiride, glibenclamide, or insulin. Quantitative data indicated that, in these elderly patients (generally defined as ≥65 years of age) with type 2 DM, DPP-4 inhibitors were associated with significant HbA(1c) reductions that ranged from ~0.7% (baseline HbA(1c) = 7.8%; P < 0.001) to 1.2% (baseline HbA(1c) = 8.3%; P < 0.05). Additional studies that did not quantify the number of elderly patients (as would a subanalysis), but did specify that elderly patients were included and that patient age did not influence the results, were incorporated in this review to support the quantitative results. No significant differences were noted in the HbA(1c)-lowering effects of these agents between elderly and younger patients. Less information about the incidence of hypoglycemia or weight gain in elderly patients was reported, but the available results suggested that the risk of hypoglycemia with DPP-4 inhibitors was not significantly different from that with placebo (sitagliptin 50 or 100 mg/d [0%] vs placebo [0%]; saxagliptin 5 mg/d [6.3%] vs placebo [8.0%]; vildagliptin 100 mg/d [2.32 events per patient-year] vs placebo [2.64 events per patient-year]; alogliptin 12.5 mg/d [8.0%] vs placebo [10.5%]) and that these agents were weight neutral (change, ≤0.9 kg). Conclusions: For elderly patients with type 2 DM, reductions in HbA(1c) after treatment with a DPP-4 inhibitor were not significantly different from those in younger patients. Use of DPP-4 inhibitors in these studies was associated with a low risk of hypoglycemia, and these agents were weight neutral. |
| | |
Authors:
|
Sherwyn L Schwartz |
Related Documents
:
|
21265304 - Characteristics of medical-surgical patients at the 86th combat support hospital during... 1395734 - Amiodarone pneumonitis. bronchoalveolar lavage findings in 15 patients and review of th... 23250344 - Aluminum phosphide poisoning known as rice tablet: a common toxicity in north iran. 21533744 - Evolution of headache in a population of young italian headache sufferers: a brief report. 19951084 - Treatment persistence and compliance with a combination of calcium and vitamin d. 12142314 - The "jaundice hotline" for the rapid assessment of patients with jaundice. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of geriatric pharmacotherapy Volume: 8 ISSN: 1876-7761 ISO Abbreviation: Am J Geriatr Pharmacother Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2011-02-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101190325 Medline TA: Am J Geriatr Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 405-18 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier HS Journals, Inc. Published by EM Inc USA.. All rights reserved. |
Affiliation:
|
Cetero Research, San Antonio, Texas; Founder and Director Diabetes & Glandular Disease Clinic, PA, San Antonio, Texas. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neuroendovascular therapies in pediatric interventional radiology.
Next Document: Use of digoxin for heart failure and atrial fibrillation in elderly patients.